Cambridge Investment Research Advisors, Inc. Galectin Therapeutics Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$27.1 Billion
Q2 2024

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 112,130 shares of GALT stock, worth $273,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares

112,130

Previous 121,141 7.44%

Holding current value

$273,597

Previous $290,000 12.76%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	SELL	$2.13 - $4.2 $19,193 - $37,846	-9,011 Reduced 7.44%	112,130 $253,000
Q1 2024 Apr 24, 2024	SELL	$1.6 - $2.44 $8,704 - $13,273	-5,440 Reduced 4.3%	121,141 $290,000
Q4 2023 Feb 09, 2024	SELL	$1.6 - $2.18 $18,545 - $25,268	-11,591 Reduced 8.39%	126,581 $210,000
Q3 2023 Oct 24, 2023	BUY	$1.38 - $1.97 $5,299 - $7,564	3,840 Added 2.86%	138,172 $265,000
Q2 2023 Jul 13, 2023	SELL	$1.32 - $2.08 $10,653 - $16,787	-8,071 Reduced 5.67%	134,332 $193,000
Q1 2023 May 11, 2023	SELL	$1.1 - $2.4 $10,084 - $22,003	-9,168 Reduced 6.05%	142,403 $299,000
Q4 2022 Feb 08, 2023	BUY	$1.03 - $1.36 $937 - $1,237	910 Added 0.6%	151,571 $171,000
Q3 2022 Oct 17, 2022	BUY	$1.31 - $2.48 $2,517 - $4,766	1,922 Added 1.29%	150,661 $0
Q2 2022 Jul 13, 2022	BUY	$1.19 - $1.74 $4,203 - $6,145	3,532 Added 2.43%	148,739 $194,000
Q1 2022 May 12, 2022	SELL	$1.61 - $2.31 $12,590 - $18,064	-7,820 Reduced 5.11%	145,207 $233,000
Q4 2021 Feb 03, 2022	SELL	$2.07 - $3.8 $23,744 - $43,589	-11,471 Reduced 6.97%	153,027 $316,000
Q3 2021 Nov 02, 2021	SELL	$2.59 - $4.15 $9,888 - $15,844	-3,818 Reduced 2.27%	164,498 $638,000
Q2 2021 Aug 10, 2021	BUY	$2.07 - $5.1 $348,414 - $858,411	168,316 New	168,316 $538,000
Q1 2021 May 07, 2021	SELL	$1.96 - $2.57 $351,929 - $461,458	-179,556 Closed	0 $0
Q4 2020 Feb 04, 2021	SELL	$2.24 - $2.87 $26,071 - $33,403	-11,639 Reduced 6.09%	179,556 $402,000
Q3 2020 Oct 29, 2020	SELL	$2.53 - $3.64 $29,681 - $42,704	-11,732 Reduced 5.78%	191,195 $510,000
Q2 2020 Jul 27, 2020	SELL	$1.66 - $3.15 $3,149 - $5,975	-1,897 Reduced 0.93%	202,927 $620,000
Q1 2020 May 08, 2020	BUY	$1.51 - $3.0 $21,357 - $42,432	14,144 Added 7.42%	204,824 $401,000
Q4 2019 Feb 04, 2020	SELL	$2.79 - $4.32 $119,869 - $185,604	-42,964 Reduced 18.39%	190,680 $545,000
Q3 2019 Nov 06, 2019	BUY	$3.0 - $4.05 $3,270 - $4,414	1,090 Added 0.47%	233,644 $857,000
Q2 2019 Aug 15, 2019	BUY	$3.61 - $5.0 $203,358 - $281,660	56,332 Added 31.97%	232,554 $0
Q1 2019 May 08, 2019	BUY	$3.86 - $6.02 $680,216 - $1.06 Million	176,222 New	176,222 $0

Others Institutions Holding GALT

# of Institutions

Shares Held

9.35M

Call Options Held

982K

Put Options Held

2.7K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $145M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Galectin Therapeutics Inc Transaction History